MedTrace Logo

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

NCT03149029 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-04-21

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma.

The drugs involved in this study are:

* Pembrolizumab (Keytruda)
* Trametinib (Mekinist)
* Dabrafenib (Tafinlar)

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a type of antibody that inhibits the cancer cell growth

DRUG

Dabrafenib

Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating

DRUG

Trametinib

Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth

Sponsors & Collaborators

Principal Investigators

  • Ryan J Sullivan, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2021-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03149029 on ClinicalTrials.gov